Xiangdong Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiangdong Li has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Zhuo-Wei Liu
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China; Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; State Key Laboratory of Neurology and Oncology Drug Development, Nanjing 210000, China; Sun Yat-sen University Cancer Center Gansu Hospital, Lanzhou 730050, China
3 shared publications - Wei Yu
Department of Urology, Peking University First Hospital, Beijing, China
2 shared publications - Yunlin Ye
Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, China
2 shared publications - Zhisong He
Department of Urology, Peking University First Hospital, Beijing, China
2 shared publications - Zhiyong Li
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
2 shared publications Chen Wei
BGI Research, Chongqing 401329, China
1 shared publication
Latest Publications
- Open Access
- 16 January 2026
- Published by Springer Nature in BMC Medicine
- Vol. 24 (1)
Comparative outcomes of distal ureterectomy vs. radical nephroureterectomy in high-risk distal ureteral urothelial carcinoma: a two-center cohort study in Northern and Southern China
This study aimed to compare radical nephroureterectomy (RNU) and distal ureterectomy (DU) in managing high-risk distal ureteral urothelial carcinoma (UC),
- 16 January 2026
- Published by Springer Nature in BMC Medicine
- Vol. 24 (1)
Open AccessComparative outcomes of distal ureterectomy vs. radical nephroureterectomy in high-risk distal ureteral urothelial carcinoma: a two-center cohort study in Northern and Southern China
This study aimed to compare radical nephroureterectomy (RNU) and distal ureterectomy (DU) in managing high-risk distal ureteral urothelial carcinoma (UC),
- 7 May 2025
- Published by Elsevier in Developmental Cell
- Vol. 60 (19) , 2594-2610.e5
Targeting VSIG4+ tissue-resident macrophages enhances T cell cytotoxicity and immunotherapy efficacy in cancer
- 7 May 2025
- Published by Elsevier in Developmental Cell
- Vol. 60 (19) , 2594-2610.e5
Targeting VSIG4+ tissue-resident macrophages enhances T cell cytotoxicity and immunotherapy efficacy in cancer
- Open Access
- 21 September 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 109 (12) , 4185-4198
SAVE Testis-sparing score: a multicenter retrospective study of a novel predictive tool for quantifying testicular tumors
Background: Testis-sparing surgery (TSS) is a safe treatment for patients with benign testicular tumors. Presently, assessments for evaluating the suitability of TSS are poorly standardized, partially because testicular anatomical elements cannot be quantitatively described. Materials and methods: The authors developed a scoring method known as the SAVE testis-sparing score based on four critical and accessible anatomical features of a testicular tumor. The SAVE score ranges from 0 to 8 and is divided into four risk classes (low, medium, high, and extremely high) to evaluate the feasibility of TSS, wherein low-risk indicates high feasibility and vice versa. This study included 444 testicular tumor patients from eight centers. Among them, 216 patients (model group: 151 patients, validation group: 65 patients) were included in the modeling analysis, and the other 228 patients from children’s centers were included in the proportion analysis. Using retrospective data, patient characteristics associated with surgical methods were identified. Furthermore, a multivariate logistic regression model was built quantify the associations between these characteristics and the surgery method. The receiver operator characteristic curve was used to evaluate the classification efficiency of SAVE. Results: The SAVE testis-sparing score includes size (tumor size as maximal diameter), available testicular tissue volume, volume ratio of the tumor to the testis, and the exophytic/endophytic properties of the tumor. The SAVE scoring system accurately classified the suitability of TSS based on the complexity of benign testicular tumors. Conclusion: The SAVE score is a reproducible and robust tool for quantitatively describing the anatomical characteristics of benign testicular tumors and guide the preoperative evaluation of TSS.
- 21 September 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 109 (12) , 4185-4198
Open AccessSAVE Testis-sparing score: a multicenter retrospective study of a novel predictive tool for quantifying testicular tumors
Background: Testis-sparing surgery (TSS) is a safe treatment for patients with benign testicular tumors. Presently, assessments for evaluating the suitability of TSS are poorly standardized, partially because testicular anatomical elements cannot be quantitatively described. Materials and methods: The authors developed a scoring method known as the SAVE testis-sparing score based on four critical and accessible anatomical features of a testicular tumor. The SAVE score ranges from 0 to 8 and is divided into four risk classes (low, medium, high, and extremely high) to evaluate the feasibility of TSS, wherein low-risk indicates high feasibility and vice versa. This study included 444 testicular tumor patients from eight centers. Among them, 216 patients (model group: 151 patients, validation group: 65 patients) were included in the modeling analysis, and the other 228 patients from children’s centers were included in the proportion analysis. Using retrospective data, patient characteristics associated with surgical methods were identified. Furthermore, a multivariate logistic regression model was built quantify the associations between these characteristics and the surgery method. The receiver operator characteristic curve was used to evaluate the classification efficiency of SAVE. Results: The SAVE testis-sparing score includes size (tumor size as maximal diameter), available testicular tissue volume, volume ratio of the tumor to the testis, and the exophytic/endophytic properties of the tumor. The SAVE scoring system accurately classified the suitability of TSS based on the complexity of benign testicular tumors. Conclusion: The SAVE score is a reproducible and robust tool for quantitatively describing the anatomical characteristics of benign testicular tumors and guide the preoperative evaluation of TSS.